Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01875770

Acronym

CAPTURE

Enrollment

Registered

2013-06-12

Start date

2013-01-31

Completion date

2021-03-03

Last updated

2021-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Vein Occlusion

Keywords

Retinal Vein Occlusion

Brief summary

This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.

Detailed description

People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 99 Years

Healthy volunteers

Inclusion criteria

* All patients who have been enrolled in the following three trials will be included in the study: A) A Pilot, Open-Label Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions., B) Extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) C) RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion - A Pharmacodynamic Approach (RELATE)

Exclusion criteria

* None

Design outcomes

Primary

Measure	Time frame	Description
Mean change from baseline in BCVA at 5 and 10 years.	10 years	Mean change from baseline in BCVA at 5 and 10 years.

Secondary

Measure	Time frame	Description
Mean change from baseline in foveal thickness at 5 and 10 years	10 years	Mean change from baseline in foveal thickness at 5 and 10 years

Countries

United States

Outcome results